Positions

Instructor in the Department of Medicine in the School of Medicine

2020 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2022 School of Medicine

Education

D.O. 2001

2001 New York Institute of Technology, College of Osteopathic Medicine

Residency, INTERNAL MEDICINE

2005 Penn State Milton S. Hershey Medical Center

Fellowship, MEDICAL ONCOLOGY

2009 Yale University

Clinical Trials

Synthekine STK-012 (Solid Tumors)

CRSP-ONC-005 (Solid Tumors)

BioNTech BNT142-01 (Solid Tumor Cancers with CLDN6 Protein)

Xencor_XmAb819-01 (Clear Cell Renal Cell Carcinoma)

Phase 2 Study of Adjuvant V940 and Pembrolizumab in Muscle-invasive Urothelial Carcinoma

Load More

Publications, Grants & Awards

• Grants (18)
• Academics Articles (181)
• Conference Pages (25)
• Book Sections (3)

Showing 1-5 of 18

A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific -T cell engager, alone or with low dose interleukin-2 or Pe

2024-2029LAVA Therapeutics N.V.

A Phase 2, Randomized, Double-blind, Placebo- and Active-comparator-controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Muscle-invasive Urothelial Carcino

2024-2029Merck Sharp & Dohme LLC.

Merck U04B

2023-2028Merck Sharp & Dohme

Xencor: ENPP3 BiTe study for ccRCC

2023-2028Xencor, Inc

BionNTech BNT142-01 (CLDN6+ solid tumors)

2023-2028BioNTech SE

DCI Centers, Cancer Types & Labs

Center for Prostate and Urologic Cancers

Offices & Contact

905 S LaSalle St
Durham, NC
27710